Monday September 25, 2017 09:28

Heathcare Press Release : 26 Jun 2017

Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Heathcare—26 Jun 17

- The 8-year follow-up results of a randomized phase 3 multicenter trial in adult patients with hematologic malignancies clearly showed more favorable results in the Grafalon(R) group - Severe GvHD-free and relapse-free survival was 34% in the